Overview
Pharmacist’s Guide to Clinical Decision Making in Anticoagulant Therapy for Stroke Prevention in Atrial Fibrillation
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
This webcast features a faculty presentation on atrial fibrillation (AF), which is the most common type of arrhythmia affecting an estimated 2.66 million people in the United States in 2010 and that number is expected to increase to as many as 12 million people by 2050. This condition is associated with substantially increased risk for ischemic stroke as well as morbidity and mortality; moreover, treatment of AF represents a significant healthcare burden with an estimated cost of $6.65 billion per year, including the costs of hospitalization, in- and outpatient physician care, and medications.
This educational activity is designed for pharmacists who interact with atrial fibrillation patients and/or manage anticoagulation therapy.
Atrial fibrillation (AF) is the most common type of arrhythmia affecting an estimated 2.66 million people in the United States in 2010 and that number is expected to increase to as many as 12 million people by 2050. This condition is associated with substantially increased risk for ischemic stroke as well as morbidity and mortality; moreover, treatment of AF represents a significant healthcare burden with an estimated cost of $6.65 billion per year, including the costs of hospitalization, in- and outpatient physician care, and medications.
Upon completion of this activity, participants will be able to:
• Recognize the risks of stroke and anticoagulation therapy in patients with atrial fibrillation according to patient characteristics, medical history, and additional patient-specific factors
• Discuss efficacy and safety data from clinical trials investigating the use of novel oral anticoagulants
• Select appropriate anticoagulation therapy in diverse atrial fibrillation patients, including those with comorbidities and concomitant medications
• Identify patient compliance issues that can inhibit anticoagulation therapy and appropriate long-term management
• Recognize the risks of stroke and anticoagulation therapy in patients with atrial fibrillation according to patient characteristics, medical history, and additional patient-specific factors
• Discuss efficacy and safety data from clinical trials investigating the use of novel oral anticoagulants
• Select appropriate anticoagulation therapy in diverse atrial fibrillation patients, including those with comorbidities and concomitant medications
• Identify patient compliance issues that can inhibit anticoagulation therapy and appropriate long-term management
Jointly provided by Purdue University College of Pharmacy and the Academy for Continued Healthcare Learning (ACHL).
Funds for this webcast have been provided by educational grants from Boehringer Ingelheim Pharmaceuticals, Inc. and Daiichi Sankyo, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 4.0 or higher and Firefox 3.0 or higher
4. Adobe Flash Player 8.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 4.0 or higher and Firefox 3.0 or higher
4. Adobe Flash Player 8.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
Edith Nutescu, PharmD, MS, FCCP
Clinical Professor
Department of Pharmacy Practice
Department of Pharmacy Systems Outcomes and Policy
Co-Director, Center for Pharmacoepidemiology & Pharmacoeconomic Research
University of Illinois at Chicago
College of Pharmacy
Clinical Professor
Department of Pharmacy Practice
Department of Pharmacy Systems Outcomes and Policy
Co-Director, Center for Pharmacoepidemiology & Pharmacoeconomic Research
University of Illinois at Chicago
College of Pharmacy
Purdue University College of Pharmacy requires that the faculty participating in a CME/CE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE activity. Purdue also requires participating faculty to disclose when unapproved/unlabeled uses of a product are discussed in a CME/CE activity.
The following relationships have been provided:
Edith Nutescu, PharmD, MS, FCC
Grants/Research Support: Janssen Pharmaceuticals, Inc.
Consultant/Speaker Bureau: Abbott Laboratories; Janssen Pharmaceuticals, Inc.; The Medicines Company
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Edoxaban
The following relationships have been provided:
Edith Nutescu, PharmD, MS, FCC
Grants/Research Support: Janssen Pharmaceuticals, Inc.
Consultant/Speaker Bureau: Abbott Laboratories; Janssen Pharmaceuticals, Inc.; The Medicines Company
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Edoxaban
Purdue University College of Pharmacy and ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
This activity will take approximately 55 minutes to complete. To receive credit, participants are required to complete the pre-test, view the online webinar and complete the post-test and evaluation forms. To receive credit, 70% must be achieved on the post-test. Pharmacist credit will be loaded to CPE Monitor within 60 days of completion. There is no fee to participate in the activity or to receive credit.
Purdue University College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This is a knowledge based continuing education activity of Purdue University, an equal access/equal opportunity institution. Universal Activity Number (UAN): 0018-9999-14-113-H04-P. This activity has been approved for a maximum of 1.00 contact hour.
Activity Type: Knowledge